DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADB246527
Title:
Signaling Components of the Anti-Tumor Hormone Somatostatin in Breast Cancer Cells
Descriptive Note:
Annual rept. 22 Sep 1997-21 Sep 1998
Corporate Author:
COLORADO UNIV HEALTH SCIENCES CENTER DENVER
Report Date:
1998-10-01
Pagination or Media Count:
17.0
Abstract:
The neuropeptide, somatostatin is an important regulatory hormone that is widely distributed throughout the body. Somatostatins actions are primarily inhibitory, and recently, it has been utilized as an antiproliferative agent against several tumor types, including breast neoplasms. Experimentally and clinically, somatostatin can inhibit breast cancer cell growth, possibly by inhibiting the secretion of growth factors, or by acting directly on the cells themselves to induce programmed cell death, or apoptosis. Despite increased clinical use, the mechanisms by which somatostatin acts to control breast cancer cell growth remain largely unknown. In this progress report, I describe studies performed to survey of numerous breast cancer cell lines to predict their usefulness as models to study somatostatin action, which comprised Aim 1 of the proposal. One cell line, MDA231 , shows a robust response to somatostatin with regard to growth factor stimulation of the mitogen activated protein kinase, ERKl2 or MAPK. Furthermore, I show preliminary data indicating that another signaling pathway, the jun n-terminal kinase JNK pathway may be activated in response to somatostatin. Aim 2. Together, these results begin to explain somatostatins ability to inhibit cell growth and induce apoptosis in breast cancer. Furthermore, identification of these target pathways defines functional assays by which the efficacy of future anti-cancer drugs can be tested.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
